Grace Miriam Ahimbisibwe
Overview
Explore the profile of Grace Miriam Ahimbisibwe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White E, Kityo C, Spyer M, Mujuru H, Nankya I, Kekitiinwa A, et al.
Lancet HIV
. 2025 Feb;
12(3):e201-e213.
PMID: 39978387
Background: ODYSSEY showed superior efficacy for dolutegravir-based antiretroviral therapy (ART) versus standard of care (SOC) in children living with HIV starting first-line or second-line ART aged 4 weeks or older....
2.
Songtaweesin W, Ahimbisibwe G, Puthanakit T, Musoke P
Curr Opin HIV AIDS
. 2024 Aug;
19(6):280-286.
PMID: 39145756
Purpose Of Review: To review the latest data on prevention of HIV vertical transmission in Asia and Africa and discuss strategic directions to achieve an AIDS free generation by 2030....
3.
Barlow-Mosha L, Ahimbisibwe G, Chappell E, Amuge P, Nanduudu A, Kaudha E, et al.
J Int AIDS Soc
. 2023 Sep;
26(9):e26174.
PMID: 37766505
Introduction: Dolutegravir-based antiretroviral therapy (ART) is the preferred antiretroviral treatment for children and adolescents living with HIV. A large surveillance study in Botswana previously raised concerns about an association between...
4.
Turkova A, White E, Kekitiinwa A, Mumbiro V, Kaudha E, Liberty A, et al.
Lancet Child Adolesc Health
. 2023 Aug;
7(10):718-727.
PMID: 37562418
Background: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to...
5.
Nakaye C, Mukiza N, Mawanda D, Kataike H, Kaganzi H, Ahimbisibwe G, et al.
AIDS Res Ther
. 2023 Mar;
20(1):18.
PMID: 36998004
Background: The Joint United Nations Programme on HIV/AIDS through the 95-95-95 target requires 95% of people living with HIV (PLHIV) on antiretroviral treatment (ART) to be virally suppressed. Viral Load...
6.
Turkova A, Waalewijn H, Chan M, Bollen P, Bwakura-Dangarembizi M, Kekitiinwa A, et al.
Lancet HIV
. 2022 Jul;
9(9):e627-e637.
PMID: 35868341
Background: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated...